Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2004

View Archived Issues

Beta adrenergic receptor targeted for treatment of male sexual dysfunction

Promising results of an HCV E1-based vaccine in hepatitis C patients

NPS Pharmaceuticals announces phase III clinical results for Preos in osteoporosis

Potent syncretic antimitotic agent by CombinatoRx

Novel bifunctional small molecule inhibitor to treat neurodegenerative diseases

Potassium channel openers for migraine and neuropathic pain from BMS

BMS-554216, a prodrug of BMS-204352, shows improved pharmacokinetics

MIV-150/Carraguard microbicide demonstrates encouraging preclinical results

Eisai to acquire Elan's Zonegran rights

Schering-Plough signs letter of intent for rights to garenoxacin

Axcan receives European marketing approval for Photobarr PDT

GenVec, PATH's MVI and NMRC expand malaria vaccine efforts

Guilford regains NAALADase inhibitor rights from Pfizer

Results from European phase III trial of Polyphenon E Ointment

GlaxoSmithKline and Theravance to form strategic alliance

Lupin to promote Zymar to U.S. pediatricians

Enrollment completed in second pivotal trial for Neurodex

Final statistical plan agreed for two pivotal Targretin trials

Intravenous Remodulin sNDA accepted for review

New phase I trial studies safety and immunogenicity of Vical's CMV vaccine

Kissei patent covers SGLT1 inhibitors for diabetes, obesity, etc.

Novel PARP inhibitors emerge from research at Kyorin

Cephalosporin derivatives with activity against MRSA disclosed

Ono discovers a novel series of PPAR inhibitors

Antiviral pyrazine derivatives designed by Toyama

Pfizer patent claims combinations of alpha-2-delta ligand/PDEV inhibitor for treatment of pain

Radioimmunotherapy with 131I-cG250 assessed in renal cell carcinoma

WX-G250 plus IFNalpha-2a reported safe and effective in renal cell carcinoma

OM-89 reduces the incidence of urinary tract infections in women

Ono claims use of ornoprostil to reduce diclofenac side effects, improve activity

Alfuzosin reduces need for surgery in acute urinary retention

CHIR-124, a novel small-molecule quinolone-based inhibitor of the CHK1 checkpoint

Ki-23057, a potent, metabolically stable inhibitor of FGFR2 characterized by Kirin

Pfizer presents data on PD-0325901, a more potent and pharmaceutically improved analogue of CI-1040

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...